The role of hydroxyurea in sickle cell disease.
Halsey
Christina
C
Department of Haematology, Great Ormond Street Hospital for Sick Children, London, UK.
Roberts
Irene A
IA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000755:Anemia, Sickle Cell / Q000097:blood / Q000188:drug therapy*; D000986:Antisickling Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002450:Cell Communication; D002648:Child; D002675:Child, Preschool; D004730:Endothelium, Vascular / Q000473:pathology; D004907:Erythrocyte Deformability / Q000187:drug effects; D004912:Erythrocytes / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006451:Hemoglobin, Sickle / Q000378:metabolism; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic; D013723:Teratogens; D017086:beta-Thalassemia / Q000188:drug therapy
D000986:Antisickling Agents; D006451:Hemoglobin, Sickle; D013723:Teratogens; D006918:Hydroxyurea